Bio (BIO) Shareholder Fort Washington Investment Advisors INC Has Cut Stake by $7.79 Million as Share Price Rose

Bio-Rad Laboratories, Inc. (NYSE:BIO) LogoInvestors sentiment increased to 1.46 in Q1 2019. Its up 0.45, from 1.01 in 2018Q4. It improved, as 29 investors sold BIO shares while 82 reduced holdings. 61 funds opened positions while 101 raised stakes. 17.40 million shares or 11.49% less from 19.66 million shares in 2018Q4 were reported. Cubist Systematic Strategies Limited Liability Corp reported 0.05% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Dynamic Capital Mgmt Limited holds 2.02% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 1,827 shares. Moreover, Amer Century Cos has 0.24% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO). Millennium Mngmt Lc reported 0.19% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Gideon Advisors Inc holds 0.19% or 1,761 shares. Commercial Bank Of America Corporation De invested 0.02% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 1,223 shares. State Treasurer State Of Michigan invested in 0.02% or 7,200 shares. Morgan Stanley holds 108,363 shares or 0.01% of its portfolio. Cibc Asset Management holds 0% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 1,081 shares. Segall Bryant And Hamill Lc holds 0.12% or 24,854 shares in its portfolio. Cramer Rosenthal Mcglynn Limited Liability Com stated it has 1.31% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). 2,200 are held by Oakbrook Lc. South Dakota Council owns 1,100 shares for 0.01% of their portfolio. 102 were accumulated by Cwm Limited Co.

Fort Washington Investment Advisors Inc decreased its stake in Bio (BIO) by 12.73% based on its latest 2019Q1 regulatory filing with the SEC. Fort Washington Investment Advisors Inc sold 25,544 shares as the company’s stock rose 6.00% . The hedge fund held 175,158 shares of the capital goods company at the end of 2019Q1, valued at $53.54 million, down from 200,702 at the end of the previous reported quarter. Fort Washington Investment Advisors Inc who had been investing in Bio for a number of months, seems to be less bullish one the $9.51 billion market cap company. The stock increased 1.04% or $3.3 during the last trading session, reaching $319.13. About 170,094 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 3.54% since August 15, 2018 and is uptrending. It has outperformed by 3.54% the S&P500.

Fort Washington Investment Advisors Inc, which manages about $44.90 billion and $8.90B US Long portfolio, upped its stake in Ishares Russell 2000 (IWM) by 30,181 shares to 54,608 shares, valued at $8.36 million in 2019Q1, according to the filing. It also increased its holding in United Technologies (NYSE:UTX) by 24,650 shares in the quarter, for a total of 772,088 shares, and has risen its stake in Kinder Morgan (NYSE:KMI).

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Finance.Yahoo.com which released: “Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance – Yahoo Finance” on June 27, 2019, also Businesswire.com with their article: “Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019 – Business Wire” published on January 03, 2019, Globenewswire.com published: “OncoCyte Announces Participation at the 2019 BIO International Convention – GlobeNewswire” on May 29, 2019. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Benzinga.com and their article: “Earnings Scheduled For May 8, 2019 – Benzinga” published on May 08, 2019 as well as Finance.Yahoo.com‘s news article titled: “Bio-Rad Laboratories Inc (BIO) Q1 2019 Earnings Call Transcript – Yahoo Finance” with publication date: May 08, 2019.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 2 analysts covering Bio-Rad Laboratories (NYSE:BIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories has $350 highest and $34000 lowest target. $343.33’s average target is 7.58% above currents $319.13 stock price. Bio-Rad Laboratories had 6 analyst reports since February 23, 2019 according to SRatingsIntel. The company was maintained on Friday, March 1 by Barclays Capital. The firm has “Buy” rating given on Friday, March 1 by Deutsche Bank.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.